240 related articles for article (PubMed ID: 9445190)
41. [A phase I study of weekly administration of CPT-11 in lung cancer].
Fukuoka M; Negoro S; Niitani H; Furue H; Hasegawa K; Hara Y; Hara N; Taguchi T
Gan To Kagaku Ryoho; 1990 May; 17(5):993-7. PubMed ID: 2159268
[TBL] [Abstract][Full Text] [Related]
42. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Tobinai K; Hotta T; Saito H; Ohnishi K; Ohno R; Ogura M; Ariyoshi Y; Takeyama K; Kobayashi T; Ohashi Y; Shirakawa S
Jpn J Clin Oncol; 1996 Dec; 26(6):455-60. PubMed ID: 9001351
[TBL] [Abstract][Full Text] [Related]
43. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
44. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
Shimada Y; Yoshino M; Wakui A; Nakao I; Futatsuki K; Sakata Y; Kambe M; Taguchi T; Ogawa N
J Clin Oncol; 1993 May; 11(5):909-13. PubMed ID: 8487053
[TBL] [Abstract][Full Text] [Related]
46. A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Ren Y; Li Y; Liu J
Int J Gynecol Cancer; 2011 May; 21(4):685-9. PubMed ID: 21543932
[TBL] [Abstract][Full Text] [Related]
47. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Pitot HC; Wender DB; O'Connell MJ; Schroeder G; Goldberg RM; Rubin J; Mailliard JA; Knost JA; Ghosh C; Kirschling RJ; Levitt R; Windschitl HE
J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
51. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
[TBL] [Abstract][Full Text] [Related]
53. Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.
Ohara T; Kobayashi Y; Yoshida A; Yoshioka N; Yahagi N; Kondo H; Tozawa A; Kiguchi K; Suzuki N
Int J Clin Oncol; 2013 Dec; 18(6):1102-6. PubMed ID: 23095879
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
[TBL] [Abstract][Full Text] [Related]
55. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
56. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Armand JP; Extra YM; Catimel G; Abigerges D; Marty M; Clavel M
Ann Oncol; 1996 Oct; 7(8):837-42. PubMed ID: 8922198
[TBL] [Abstract][Full Text] [Related]
57. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
58. Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Calvo E; Cortés J; González-Cao M; Rodríguez J; Aramendía JM; Fernández-Hidalgo O; Martín-Algarra S; Salgado JE; Martínez-Monge R; de Irala J; Brugarolas A
Oncology; 2002; 63(3):254-65. PubMed ID: 12381905
[TBL] [Abstract][Full Text] [Related]
59. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
[TBL] [Abstract][Full Text] [Related]
60. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Ilson DH
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
